FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Siu Christine
2. Issuer Name and Ticker or Trading Symbol

Eidos Therapeutics, Inc. [ EIDX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CFO and Secretary
(Last)          (First)          (Middle)

C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2000
3. Date of Earliest Transaction (MM/DD/YYYY)

12/3/2019
(Street)

SAN FRANCISCO, CA 94104
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/3/2019  M  10000 A$0.59 46470 D  
Common Stock 12/3/2019  S  600 D$57.8212 (1)45870 D  
Common Stock 12/3/2019  S  5400 D$58.9504 (2)40470 D  
Common Stock 12/3/2019  S  4000 D$59.6457 (3)36470 D  
Common Stock 12/4/2019  M  10000 A$0.59 46470 D  
Common Stock 12/4/2019  S  8800 D$58.599 (4)37670 D  
Common Stock 12/4/2019  S  1200 D$59.3932 (5)36470 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $0.59 12/3/2019  M     10000   (6)12/21/2027 Common Stock 10000 $0.00 172191 D  
Stock Option (right to buy) $0.59 12/4/2019  M     10000   (6)12/21/2027 Common Stock 10000 $0.00 162191 D  

Explanation of Responses:
(1) Represents the weighted average sale price of the shares sold from $57.275 to $58.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 through 5.
(2) Represents the weighted average sale price of the shares sold from $58.37 to $59.225 per share.
(3) Represents the weighted average sale price of the shares sold from $59.37 to $60.35 per share.
(4) Represents the weighted average sale price of the shares sold from $58.11 to $59.10 per share.
(5) Represents the weighted average sale price of the shares sold from $59.125 to $59.58 per share.
(6) The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Siu Christine
C/O EIDOS THERAPEUTICS, INC.
101 MONTGOMERY STREET, SUITE 2000
SAN FRANCISCO, CA 94104


CFO and Secretary

Signatures
/s/ Franco Valle, as Attorney-in-Fact12/5/2019
**Signature of Reporting PersonDate

Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Eidos Therapeutics Charts.
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Eidos Therapeutics Charts.